Abstract Number: 1770 • ACR Convergence 2021
Interim Analysis of Cohort 1 in the Mesenchymal Stromal Cell Trial in Systemic Lupus Erythematosis: Safety and Data Management During the Pandemic
Background/Purpose: There is heightened interest in the use of mesenchymal stromal cells (MSCs) for the treatment of autoimmune diseases. There are a number of reports…Abstract Number: 0131 • ACR Convergence 2021
Association of Numeracy with Medication Non-Adherence in Systemic Lupus Erythematosus
Background/Purpose: Over 33% of U.S. adults have limited health literacy or numeracy. Limited health literacy and numeracy have been associated with higher disease activity and…Abstract Number: 0330 • ACR Convergence 2021
Serologic Phenotypes Distinguish SLE Patients with Myositis And/or Interstitial Lung Disease (ILD)
Background/Purpose: To determine if a serologic phenotype can be identified in SLE patients with myositis and/or ILD.Methods: Adult SLE patients (without myositis or ILD at…Abstract Number: 0347 • ACR Convergence 2021
Longitudinal ANA Titers in SLE and ANA+ Controls
Background/Purpose: Antinuclear or anticellular antibodies (ANAs), are a hallmark of systemic lupus erythematosus (SLE). ANAs are also a marker of subclinical autoimmunity, with ~13% of…Abstract Number: 0523 • ACR Convergence 2021
Transcriptional Subsetting of SLE Patient Cohorts Based on Metabolic Pathway Activity
Background/Purpose: Systemic lupus erythematosus is a highly complex, heterogeneous, autoimmune disorder, with diverse clinical presentation and innate and adaptive immune system involvement. There is a…Abstract Number: 0613 • ACR Convergence 2021
Racial/Ethnic Disparities in Prescription Medications in a Large Urban Medical Center
Background/Purpose: African Americans and Hispanics with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) continue to have worse disease-related health outcomes relative to Whites. This…Abstract Number: 0784 • ACR Convergence 2021
Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-Onset Systemic Lupus Erythematosus in North America
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) has higher rates of lupus nephritis (LN) than adult-onset SLE, often requiring intensive immunosuppression. This study examined North American…Abstract Number: 0871 • ACR Convergence 2021
The Association of Hydroxychloroquine Dosing with Adverse Cardiovascular Events in Patients with Systemic Lupus Erythematosus
Background/Purpose: Current guidelines recommend use of hydroxychloroquine (HCQ) at doses not exceeding 5mg/kg based solely on the increased risk of retinopathy at higher doses. This…Abstract Number: 0888 • ACR Convergence 2021
Disease Flares in Lupus Are Concordant with Ruminococcus Blautia Gnavus Blooms Within Unstable Gut Microbiota Communities
Background/Purpose: Systemic Lupus Erythematosus is the archetypic systemic autoimmune disease in which dysbiosis in the gut microbiome has been postulated to contribute to disease development…Abstract Number: 0989 • ACR Convergence 2021
Risk Factors for Hydroxychloroquine Retinopathy and Its Subtypes – Prospective Adjudication Analysis of 4,899 Incident Users
Background/Purpose: Hydroxychloroquine (HCQ) is a key treatment for patients with lupus and other rheumatic diseases; however, the known risk factors for HCQ retinopathy (its major…Abstract Number: 1160 • ACR Convergence 2021
Evaluation of HCQ Side Effects in New and Prevalent Users over a 20 Year Period Using a Large Database
Background/Purpose: Despite being used for more than 70 years as a conventional (cs) DMARD, very little is known about the overall side effect (SE) profile…Abstract Number: 1268 • ACR Convergence 2021
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Comparison of Machine Learning Methods
Background/Purpose: Nearly 20% of pregnancies in patients with Systemic lupus erythematosus (SLE) result in an adverse pregnancy outcome (APO); early identification of women with SLE…Abstract Number: 1284 • ACR Convergence 2021
One Third of Lupus Nephritis Patients Classified as Complete Responders Continue to Accrue Progressive Renal Damage Despite Resolution of Proteinuria
Background/Purpose: Up to 40% of individuals with lupus nephritis (LN) develop chronic kidney disease (CKD). Biopsy studies have revealed that patients with SLE can have…Abstract Number: 1301 • ACR Convergence 2021
Early Increase in Circulating Memory B Cells Portends Clinical Response to Treatment in Pooled Data from Three Phase III Trials of Belimumab
Background/Purpose: Belimumab blocks soluble B cell activating factor (BAFF) and is the only to date approved targeted treatment for systemic lupus erythematosus (SLE). Identification of…Abstract Number: 1462 • ACR Convergence 2021
Hydroxychloroquine Dose and the Risk of Systemic Lupus Erythematosus Flares
Background/Purpose: Hydroxychloroquine (HCQ) is an important treatment for systemic lupus erythematosus (SLE), known to reduce disease activity and flares. To minimize the risk of toxicity,…
- « Previous Page
- 1
- …
- 56
- 57
- 58
- 59
- 60
- …
- 119
- Next Page »